Blog

PHARMAC is pleased to announce the approval of an agreement with Bayer New Zealand Limited for the listing and supply ...

The agenda for the July 2015 PBAC meeting is now available on the PBS website. ...

The January 2015 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. The Schedule includes the ...

Fact sheets on the administration, handling and infrastructure fee, premium free dispensing incentive and adjusted tier 2 pricing have been ...

[:content [\N \o \v \e \m \b \e \r \space \2 \8 \, \space \2 \0 \1 \3 \space \- \  \  \A \b \b \V \i \e \space \a \n \n \o \u \n \c \e \d \space \t \o \d \a \y \space \t \h \a \t \space \H \e \a \l \t \h \space \C \a \n \a \d \a \space \h \a \s \space \a \p \p \r \o \v \e \d \space \H \u \m \i \r \a \  \( \a \d \a \l \i \m \u \m \a \b \) \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t \space \o \f \space \a \d \u \l \t \space \p \a \t \i \e \n \t \s \space \w \i \t \h \space \m \o \d \e \r \a \t \e \l \y " ..."]]

[:content [\1 \space \A \p \r \i \l \space \2 \0 \1 \4 \space \- \  \T \h \e \space \I \Q \W \i \G \  \r \e \a \s \s \e \s \s \e \d \space \t \h \e \space \a \n \t \i \v \i \r \a \l \space \d \r \u \g \space \c \o \m \b \i \n \a \t \i \o \n \space \r \i \l \p \i \v \i \r \i \n \e \/ \e \m \t \r \i \c \i \t \a \b \i \n \e \/ \t \e \n \o \f \o \v \i \r \. \space \I \n \space \e \a \r \l \y \space \2 \0 \1 \2 \, \space \t \h \e \space \c \o \m \b \i \n \a \t \i \o \n \space \w \a \s \space \a \p \p \r \o \v \e \d \space \f \o \r \space \t \h \e \space \t \r \e \a \t \m \e \n \t " ..."]]

NICE is making progress in improving access to new cancer treatments but it needs to take proper account of true innovation ...

NICE has joined a global group of organisations whose goal is to speed up the development and delivery of new, ...

[:content [\1 \0 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \  \P \e \o \p \l \e \space \i \n \space \O \n \t \a \r \i \o \space \a \n \d \space \A \t \l \a \n \t \i \c \space \C \a \n \a \d \a \space \f \a \c \e \space \f \i \n \a \n \c \i \a \l \space \h \a \r \d \s \h \i \p \space \t \h \a \t \space \o \t \h \e \r \space \C \a \n \a \d \i \a \n \s \space \d \o \n \' \t \space \w \h \e \n \space \i \t \space \c \o \m \e \s \space \t \o " ..."]]

The Alliance for Safe Biologic Medicines (ASBM) today condemned recent announcements by Australian Health Minister Sussan Ley and the Pharmaceutical Benefits Advisory Committee (PBAC) ...

Another new cancer drug from Roche, this time for treating leukaemia, has been rejected by Britain's healthcare cost-effectiveness agency NICE ...

[:content [\N \I \C \E \space \h \a \s \space \p \u \b \l \i \s \h \e \d \space \f \i \n \a \l \space \g \u \i \d \a \n \c \e \space \r \e \c \o \m \m \e \n \d \i \n \g \space \t \h \e \space \u \s \e \space \o \f \space \a \f \l \i \b \e \r \c \e \p \t \  \a \s \space \a \n \space \o \p \t \i \o \n \space \f \o \r \space \t \r \e \a \t \i \n \g \space \p \a \t \i \e \n \t \s \space \w \i \t \h \  \w \e \t \space \a \g \e \- \r \e \l \a \t \e \d \space \m \a \c \u \l \a \r \space \d \e \g \e \n \e \r \a \t \i \o \n \space \( \A \M \D \) \. \  \A \f \l \i \b \e \r \c \e \p \t " ..."]]

NICE has today published preliminary recommendations on ciclosporin (Ikervis, Santen Pharmaceutical) for treating severe keratitis in adults with dry eye disease ...

16 December 2013 - The IQWiG has completed its reassessment of vemurafenib (Zelboraf), a drug used to treat adults with a  certain type ...